Theriva™ Biologics to Reschedule Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results

November 10, 2022 07:00 ET

-Conference call to be held on Friday, November 11 at 8:30 a.m. ET-

ROCKVILLE, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a conference call on Friday, November 11, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2022 and provide a corporate update. The call was originally scheduled for Thursday, November 10, 2022, at 8:30 a.m. ET.

Individuals may participate in the live call via telephone by dialing 1-888-254-3590 (domestic) or 1-929-477-0402 (international) and using the conference ID: 5687287. Participants are asked to dial in 15 minutes before the start of the call to register. Investors and the public can access the live and archived webcast of this call via the “Investors” section of the company’s website,, under “Events” or by clicking here, for 90 days after the call.

About Theriva Biologics, Inc.

Theriva Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company’s subsidiary VCN Biosciences, S.L. (VCN), has been developing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients; and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics’ website at

For further information, please contact:

Investor Relations:

Chris Calabrese

LifeSci Advisors, LLC